|
1
|
Takimoto CH: New Antifolates: Pharmacology
and Clinical Applications. Oncologist. 1:68–81. 1996.PubMed/NCBI
|
|
2
|
Neradil J, Pavlasova G and Veselska R: New
mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of
methotrexate in cancer cells. Klin Onkol. 25:2S87–2S92.
2012.PubMed/NCBI
|
|
3
|
Sterba J, Valík D, Bajciová V, Kadlecová
V, Gregorová V and Mendelová D: High-dose methotrexate and/or
leucovorin rescue for the treatment of children with lymphoblastic
malignancies: do we really know why, when and how? Neoplasma.
52:456–463. 2005.PubMed/NCBI
|
|
4
|
Sterba J, Dusek L, Demlova R and Valik D:
Pretreatment plasma folate modulates the pharmacodynamic effect of
high-dose methotrexate in children with acute lymphoblastic
leukemia and non-Hodgkin lymphoma: ‘folate overrescue’ concept
revisited. Clin Chem. 52:692–700. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang JJ and Li GJ: Relationship between
RFC gene expression and intracellular drug concentration in
methotrexate-resistant osteosarcoma cells. Genet Mol Res.
13:5313–5321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fotoohi AK and Albertioni F: Mechanisms of
antifolate resistance and methotrexate efficacy in leukemia cells.
Leuk Lymphoma. 49:410–426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Assaraf YG: Molecular basis of antifolate
resistance. Cancer Metastasis Rev. 26:153–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Veselska R, Neradil J, Nekulova M,
Dobrucka L, Vojtesek B, Sterba J and Zitterbart K: Intracellular
distribution of the ΔNp73 protein isoform in medulloblastoma cells:
a study with newly generated rabbit polyclonal antibodies. Histol
Histopathol. 28:913–924. 2013.PubMed/NCBI
|
|
9
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holmboe L, Andersen AM, Mørkrid L, Slørdal
L and Hall KS: High dose methotrexate chemotherapy:
pharmacokinetics, folate and toxicity in osteosarcoma patients. Br
J Clin Pharmacol. 73:106–114. 2012. View Article : Google Scholar :
|
|
11
|
Rahiem Ahmed YAA and Hasan Y: Prevention
and management of high dose methotrexate toxicity. J Cancer Sci
Ther. 5:106–112. 2013.
|
|
12
|
Cohen IJ1 and Wolff JE: How long can
folinic acid rescue be delayed after high-dose methotrexate without
toxicity? Pediatr Blood Cancer. 61:7–10. 2014. View Article : Google Scholar
|
|
13
|
Najim N, Podmore ID, McGown A and Estlin
EJ: Methionine restriction reduces the chemosensitivity of central
nervous system tumour cell lines. Anticancer Res. 29:3103–3108.
2009.PubMed/NCBI
|
|
14
|
Assaraf YG, Ifergan I, Kadry WN and Pinter
RY: Computer modelling of antifolate inhibition of folate
metabolism using hybrid functional petri nets. J Theor Biol.
240:637–647. 2006. View Article : Google Scholar
|
|
15
|
Bastian L, Einsiedel HG, Henze G, Seeger K
and Shalapour S: The sequence of application of methotrexate and
histone deacetylase inhibitors determines either a synergistic or
an antagonistic response in childhood acute lymphoblastic leukemia
cells. Leukemia. 25:359–361. 2011. View Article : Google Scholar
|
|
16
|
Huang Y: Pharmacogenetics/genomics of
membrane transporters in cancer chemotherapy. Cancer Metastasis
Rev. 26:183–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon SA, Choi JR, Kim JO, Shin JY, Zhang X
and Kang JH: Influence of reduced folate carrier and dihydrofolate
reductase genes on methotrexate-induced cytotoxicity. Cancer Res
Treat. 42:163–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nazki FH, Sameer AS and Ganaie BA: Folate:
metabolism, genes, polymorphisms and the associated diseases. Gene.
533:11–20. 2014. View Article : Google Scholar
|
|
19
|
Furuta E, Okuda H, Kobayashi A and Watabe
K: Metabolic genes in cancer: their roles in tumor progression and
clinical implications. Biochim Biophys Acta. 1805:141–152.
2010.PubMed/NCBI
|
|
20
|
Rots MG, Willey JC, Jansen G, van Zantwijk
CH, Noordhuis P, DeMuth JP, Kuiper E, Veerman AJ, Pieters R and
Peters GJ: mRNA expression levels of methotrexate
resistance-related proteins in childhood leukemia as determined by
a standardized competitive template-based RT-PCR method. Leukemia.
14:2166–2175. 2000. View Article : Google Scholar
|
|
21
|
Nilubol N, Zhang L, Shen M, Zhang YQ, He
M, Austin CP and Kebebew E: Four clinically utilized drugs were
identified and validated for treatment of adrenocortical cancer
using quantitative high-throughput screening. J Transl Med.
10:1982012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Capelôa T, Caramelo F, Fontes-Ribeiro C,
Gomes C and Silva AP: Role of methamphetamine on glioblastoma
cytotoxicity induced by Doxorubicin and methotrexate. Neurotox Res.
26:216–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan KH, Lee LM, Hsieh MC, Yan MD, Yao CJ,
Chang PY, Chen TL, Chang HY, Cheng AL, Lai GM and Chuang SE:
Aspirin antagonizes the cytotoxic effect of methotrexate in lung
cancer cells. Oncol Rep. 30:1497–1505. 2013.PubMed/NCBI
|
|
24
|
Hattangadi DK, DeMasters GA, Walker TD,
Jones KR, Di X, Newsham IF and Gewirtz DA: Influence of p53 and
caspase 3 activity on cell death and senescence in response to
methotrexate in the breast tumor cell. Biochem Pharmacol.
68:1699–1708. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hellwinkel OJ, Müller J, Pollmann A and
Kabisch H: Osteosarcoma cell lines display variable individual
reactions on wildtype p53 and Rb tumour-suppressor transgenes. J
Gene Med. 7:407–419. 2005. View Article : Google Scholar
|
|
26
|
Jordan JJ, Inga A, Conway K, Edmiston S,
Carey LA, Wu L and Resnick MA: Altered-function p53 missense
mutations identified in breast cancers can have subtle effects on
transactivation. Mol Cancer Res. 8:701–716. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Künkele A, De Preter K, Heukamp L, Thor T,
Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE,
Speleman F, Schramm A, Eggert A and Schulte JH: Pharmacological
activation of the p53 pathway by nutlin-3 exerts anti-tumoral
effects in medulloblastomas. Neuro Oncol. 14:859–869. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Termuhlen AM, Smith LM, Perkins SL, Lones
M, Finlay JL, Weinstein H, Gross TG and Abromowitch M: Disseminated
lymphoblastic lymphoma in children and adolescents: results of the
COG A5971 trial: a report from the Children’s Oncology Group. Br J
Haematol. 162:792–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
